Risk factors

Pasithea Therapeutics (KTTA) risk factors

Item 1A of every Pasithea Therapeutics Corp. 10-K on file, and what changed from one year to the next.

Open KTTA in Gloomberb →
  • FY2025 10-K risk factors

    43 risks, 2 dropped, 9 reworded since the prior year. Net losses increased to $20.4 million in 2025, bringing the accumulated deficit to $70.0 million. Received a Nasdaq minimum bid price deficiency notice on February 20, 2026. Added references to the OBBBA tax legislation.

    Filed Mar 30, 2026
  • FY2024 10-K risk factors

    45 risks. Clinical stage biotechnology company with operating losses and an accumulated deficit of $49.6 million.

    Filed Mar 24, 2025